CDMO collaborates with synthetic DNA provider for biologic drug development

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ gorodenkoff)
(Image: Getty/ gorodenkoff)

Related tags: Biologics, Drug development, Dna, Antibody, discovery services, Oncology, Pain

Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.

Per the agreement, customers of the contract development and manufacturing organization (CDMO), LakePharma, will have access to Twist’s antibody discovery and optimization platforms as a service offering.

One of these platforms has the capability to generate therapeutic antibodies against a class of protein drug targets known as G Protein-coupled receptors (GPCRs), which have been investigated for the involvement in multiple disease classes such as inflammation, cancer, metabolism, respiratory, and pain.

According to the Twist spokesperson, through the partnership the companies “may be able to expedite discovery and development timelines while beginning with improved antibody therapeutics.”

The spokesperson told us that the company “writes DNA from scratch,”​ enabling it to create any specific combination and premutation, which cannot be created using traditional random mutagenesis library development as that typically misses large sections or overrepresents others.

Additionally, Twist can synthesize DNA libraries for any given target, a strength that will be leveraged with LakePharma’s integrated discovery and development services.

Twist invested $50m (€44.57m) in April 2018 to advance its silicon-based DNA Synthesis Platform​ which can be used to support drug discovery, as well as next-generation sequencing for target enrichment and detection of disease-causing genetic variations. 

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 19-Oct-2020 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Related suppliers

Follow us

Products

View more

Webinars